Placebo News and Research

RSS

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the Therapeutic Goods Administration of Australia has approved KALYDECO (ivacaftor) for people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.

10 Jul 2013

Study shows rates of brain loss caused by aging and AD are higher for women

The rates of regional brain loss and cognitive decline caused by aging and the early stages of Alzheimer's disease (AD) are higher for women and for people with a key genetic risk factor for AD, say researchers at the University of California, San Diego School of Medicine in a study published online July 4 in the American Journal of Neuroradiology.

10 Jul 2013

Soy protein supplement does not reduce recurrence of prostate cancer post radical prostatectomy

Among men who had undergone radical prostatectomy, daily consumption of a beverage powder supplement containing soy protein isolate for 2 years did not reduce or delay development of biochemical recurrence of prostate cancer compared to men who received placebo, according to a study in the July 10 issue of JAMA.

10 Jul 2013

Individualised care can make huge difference in older patients with type 2 diabetes

More than a quarter of over 70s with type 2 diabetes could benefit simply from improving communication and education in the clinic, new research has revealed. A study led by the University of Exeter Medical School and published in The Lancet found that 27 percent achieved better glycaemic control through individualised care alone.

9 Jul 2013

Soligenix announces personalized medicine collaboration with SciClone

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced a personalized medicine collaboration with SciClone Pharmaceuticals in the Company's oral mucositis clinical program with SGX942.

8 Jul 2013

Study describes how human mammary gland becomes highly sensitive to insulin during lactation

Why do so many mothers have difficulty making enough milk to breastfeed? A new study by scientists at Cincinnati Children's Hospital Medical Center and the University of California Davis adds to their previous research implicating insulin's role in lactation success.

6 Jul 2013

Gerovital H3 may be making a comeback, warns BUSM researcher

Despite it being more than 30 years since the "fountain of youth drug" Gerovital H3 was banned in the United States, it may be making a comeback. In an editorial published in this month's Journal of the American Geriatrics Society BUSM researcher Thomas Perls, MD, points out that a few U.S.-based anti-aging and longevity clinics have begun to advertise Gerovital H3 in pill form and as intravenous infusions despite the fact that the U.S. Food and Drug Administration banned it in 1982.

4 Jul 2013

MGN1703 drug provides a new treatment approach to colorectal cancer

New data on an emerging treatment that aims to fight colorectal cancer by stimulating the immune system have been presented at the ESMO 15th World Congress on Gastrointestinal Cancer.

4 Jul 2013

Pergamum: LL-37 Phase I/II trial meets primary end-point in patients with venous leg ulcers

Pergamum AB, a portfolio company of Karolinska Development AB, announced today that the primary safety and tolerability end-point was met in the randomized Phase I/II trial of LL-37 for treatment of venous leg ulcers.

4 Jul 2013

Abiraterone can prolong overall survival and delay severe pain in prostate cancer patients

Abiraterone acetate (abiraterone for short, trade name: Zytiga) has been approved in Germany since December 2012 for men with metastatic prostate cancer that is not responsive to hormone blockade, who only have mild symptoms or so far none at all, and in whom chemotherapy is not yet indicated.

3 Jul 2013

Salsalate lowers blood glucose and improves glycemic control in T2D, say scientists

Joslin scientists report that salsalate, a drug used to treat arthritis, lowers blood glucose and improves glycemic control in type 2 diabetes. These findings, which were published today by the Annals of Internal Medicine, provide additional evidence that salsalate may be an effective drug to treat type 2 diabetes.

3 Jul 2013

Idera Pharmaceuticals reports Phase 1 clinical trial results of IMO-8400

Idera Pharmaceuticals, Inc. announced results of a Phase 1 clinical trial of IMO-8400, a first-in-class antagonist of Toll-like Receptors 7, 8, and 9 being developed for potential applications in autoimmune and inflammatory diseases.

2 Jul 2013

OBI advances Phase IIb clinical trial of Oxycyte for treatment of TBI

Oxygen Biotherapeutics, Inc., ("OBI") (NASDAQ: OXBT), today announced enrollment of the first subject in the second cohort of its global Phase IIb clinical trial to investigate the safety and tolerability of Oxycyte® in patients with severe, non-penetrating traumatic brain injury ("STOP-TBI").

2 Jul 2013

Researchers find new treatment option for schizophrenia

A research group led by professor Jesper Ekelund showed that by giving a very large dose of famotidine (200 mg daily), sufficient amounts of the drug are able to penetrate the so-called blood-brain barrier to affect the histamine system in the brain.

1 Jul 2013

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and an application for marketing authorization to the European Medicines Agency for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

1 Jul 2013

Biomarker indicates which women are at risk for breast cancer recurrence after tamoxifen

A biomarker reflecting expression levels of two genes in tumor tissue may be able to predict which women treated for estrogen-receptor (ER)-positive breast cancer should receive a second estrogen-blocking medication after completing tamoxifen treatment.

30 Jun 2013

Transplanted bone marrow stem cells in patients with type 2 diabetes reduce insulin use

A study carried out in India examining the safety and efficacy of self-donated (autologous), transplanted bone marrow stem cells in patients with type 2 diabetes (TD2M), has found that patients receiving the transplants, when compared to a control group of TD2M patients who did not receive transplantation, required less insulin post-transplantation.

30 Jun 2013

Brisdelle receives FDA approval to treat hot flashes associated with menopause

The U.S. Food and Drug Administration today approved Brisdelle (paroxetine) to treat moderate to severe hot flashes (vasomotor symptoms) associated with menopause. Brisdelle, which contains the selective serotonin reuptake inhibitor paroxetine mesylate, is currently the only non-hormonal treatment for hot flashes approved by the FDA.

29 Jun 2013

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for approval of LEMTRADA (alemtuzumab) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features.

28 Jun 2013

Eleven Biotherapeutics reports positive results from EBI-005 Phase 1b/2a study in patients with DED

Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today positive topline clinical results from a 6-week randomized, double-masked, placebo-controlled Phase 1b/2a study of EBI-005 in patients with dry eye disease.

28 Jun 2013

Placebo News and Research

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Study shows rates of brain loss caused by aging and AD are higher for women

Soy protein supplement does not reduce recurrence of prostate cancer post radical prostatectomy

Individualised care can make huge difference in older patients with type 2 diabetes

Soligenix announces personalized medicine collaboration with SciClone

Study describes how human mammary gland becomes highly sensitive to insulin during lactation

Gerovital H3 may be making a comeback, warns BUSM researcher

MGN1703 drug provides a new treatment approach to colorectal cancer

Pergamum: LL-37 Phase I/II trial meets primary end-point in patients with venous leg ulcers

Abiraterone can prolong overall survival and delay severe pain in prostate cancer patients

Salsalate lowers blood glucose and improves glycemic control in T2D, say scientists

Idera Pharmaceuticals reports Phase 1 clinical trial results of IMO-8400

OBI advances Phase IIb clinical trial of Oxycyte for treatment of TBI

Researchers find new treatment option for schizophrenia

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Biomarker indicates which women are at risk for breast cancer recurrence after tamoxifen

Transplanted bone marrow stem cells in patients with type 2 diabetes reduce insulin use

Brisdelle receives FDA approval to treat hot flashes associated with menopause

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

Eleven Biotherapeutics reports positive results from EBI-005 Phase 1b/2a study in patients with DED

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News